본문 바로가기
KERD
논문KCI 등재

Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer

Kirk Nicole A.|Kim Kee-Beom|Park Kwon-Sik
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2022.12|Experimental and Molecular Medicine|제54권 |pp. 2118-2127|DOI 10.1038/s12276-022-00905-x

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Tumor suppressor genes (TSGs) are often involved in maintaining homeostasis. Loss of tumor suppressor functions causes cellular plasticity that drives numerous types of cancer, including small-cell lung cancer (SCLC), an aggressive type of lung cancer. SCLC is largely driven by numerous loss-of-function mutations in TSGs, often in those encoding chromatin modifiers. These mutations present a therapeutic challenge because they are not directly actionable. Alternatively, understanding the resulting molecular changes may provide insight into tumor intervention strategies. We hypothesize that despite the heterogeneous genomic landscape in SCLC, the impacts of mutations in patient tumors are related to a few important pathways causing malignancy. Specifically, alterations in chromatin modifiers result in transcriptional dysregulation, driving mutant cells toward a highly plastic state that renders them immune evasive and highly metastatic. This review will highlight studies in which imbalance of chromatin modifiers with opposing functions led to loss of immune recognition markers, effectively masking tumor cells from the immune system. This review also discusses the role of chromatin modifiers in maintaining neuroendocrine characteristics and the role of aberrant transcriptional control in promoting epithelial-to-mesenchymal transition during tumor development and progression. While these pathways are thought to be disparate, we highlight that the pathways often share molecular drivers and mediators. Understanding the relationships among frequently altered chromatin modifiers will provide valuable insights into the molecular mechanisms of SCLC development and progression and therefore may reveal preventive and therapeutic vulnerabilities of SCLC and other cancers with similar mutations.

Abstract

Tumor suppressor genes (TSGs) are often involved in maintaining homeostasis. Loss of tumor suppressor functions causes cellular plasticity that drives numerous types of cancer, including small-cell lung cancer (SCLC), an aggressive type of lung cancer. SCLC is largely driven by numerous loss-of-function mutations in TSGs, often in those encoding chromatin modifiers. These mutations present a therapeutic challenge because they are not directly actionable. Alternatively, understanding the resulting molecular changes may provide insight into tumor intervention strategies. We hypothesize that despite the heterogeneous genomic landscape in SCLC, the impacts of mutations in patient tumors are related to a few important pathways causing malignancy. Specifically, alterations in chromatin modifiers result in transcriptional dysregulation, driving mutant cells toward a highly plastic state that renders them immune evasive and highly metastatic. This review will highlight studies in which imbalance of chromatin modifiers with opposing functions led to loss of immune recognition markers, effectively masking tumor cells from the immune system. This review also discusses the role of chromatin modifiers in maintaining neuroendocrine characteristics and the role of aberrant transcriptional control in promoting epithelial-to-mesenchymal transition during tumor development and progression. While these pathways are thought to be disparate, we highlight that the pathways often share molecular drivers and mediators. Understanding the relationships among frequently altered chromatin modifiers will provide valuable insights into the molecular mechanisms of SCLC development and progression and therefore may reveal preventive and therapeutic vulnerabilities of SCLC and other cancers with similar mutations.

참고문헌 (101)

  1. Rodriguez, E., "Small Cell Lung Cancer : Past, Present, and Future", Curr. Oncol. Rep, 12, pp.327~334 (2010)
  2. American Cancer Society, "Cancer Facts & Figures 2022", ~ (2022)
  3. Califano, R., "Management of Small Cell Lung Cancer", Drugs, 72, pp.471~490 (2012)
  4. Byers, L. A., "Small cell lung cancer : Where do we go from here?", Cancer, 121, pp.664~672 (2015)
  5. Rudin, C. M., "Small-cell lung cancer", Nat. Rev. Dis. Prim, 7, pp.1~20 (2021)
  6. Friedlaender, A., "KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures", Cancer Treat. Rev, 85, pp.101978~ (2020)
  7. Jordan, E. J., "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies", Cancer Disco, 7, pp.596~609 (2017)
  8. George, J., "Comprehensive genomic profiles of small cell lung cancer", Nature, 524, pp.47~53 (2015)
  9. Peifer, M., "Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer", Nat. Genet, 44, pp.1104~1110 (2012)
  10. Augert, A., "Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D", MLL2 : CALGB 151111(Alliance), 2017, pp.12, 704~713
  11. Meuwissen, R., "Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model", Cancer Cell, 4, pp.181~189 (2003)
  12. Park, K. -S., "Characterization of the cell of origin for small cell lung cancer", Cell Cycle, 10, pp.2806~2815 (2011)
  13. Schaffer, B. E., "Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma", Cancer Res, 70, pp.3877~3883 (2010)
  14. van Meerbeeck, J. P., "Small-cell lung cancer", Lancet, 378, pp.1741~1755 (2011)
  15. Gazdar, A. F., "Small-cell lung cancer : what we know, what we need to know and the path forward", Nat. Rev. Cancer, 17, pp.765~ (2017)
  16. Wang, S., "Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages", Sci. Rep, 7, pp.1~13 (2017)
  17. Reck, M., "Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer : results from a randomized, double-blind, multicenter phase 2 trial†", Ann. Oncol, 24, pp.75~83 (2013)
  18. Topalian, S. L., "Immune Checkpoint Blockade : A Common Denominator Approach to Cancer Therapy", Cancer Cell, 27, pp.450~461 (2015)
  19. Wei, S. C., "Fundamental Mechanisms of Immune Checkpoint Blockade Therapy", Cancer Disco, 8, pp.1069~1086 (2018)
  20. Hellmann, M. D., "Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer", Cancer Cell, 33, pp.853~861.e4 (2018)
  21. Ishii, H., "Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer", J. Thorac. Oncol, 10, pp.426~430 (2015)
  22. Yamane, H., "Programmed cell death protein 1 and programmed deathligand 1 are expressed on the surface of some small-cell lung cancer lines", Am. J. Cancer Res, 5, pp.1553~1557 (2015)
  23. Eerola, A. K., "A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma", Clin. Cancer Res. J. Am. Assoc. Cancer Res, 6, pp.1875~1881 (2000)
  24. Busch, S. E., "Lung Cancer Subtypes Generate Unique Immune Responses", J. Immunol, 197, pp.4493~4503 (2016)
  25. Chan, J. M., "Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer", Cancer Cell, 39, pp.1479~1496.e18 (2021)
  26. Doyle, A., "Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer", J. Exp. Med, 161, pp.1135~1151 (1985)
  27. Funa, K., "Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors", Lab. Investig. J. Tech. Methods Pathol, 55, pp.186~193 (1986)
  28. Restifo, N. P., "Identification of human cancers deficient in antigen processing", J. Exp. Med, 177, pp.265~272 (1993)
  29. Burr, M. L., "An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer", Cancer Cell, 36, pp.385~401.e8 (2019)
  30. Schuettengruber, B., "Genome Regulation by Polycomb and Trithorax Proteins", Cell, 128, pp.735~745 (2007)
  31. Kaer, L. V., "TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+T cells", Cell, 71, pp.1205~1214 (1992)
  32. Sandberg, J. K., "TAP1-deficient mice select a CD8+T cell repertoire that displays both diversity and peptide specificity", Eur. J. Immunol, 26, pp.288~293 (1996)
  33. Weiskopf, K., "CD47-blocking immunotherapies stimulate macrophagemediated destruction of small-cell lung cancer", J. Clin. Invest, 126, pp.2610~2620 (2016)
  34. Dora, D., "Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and-Low Small Cell Lung Cancer", Biology, 10, pp.502~ (2021)
  35. Jiang, P., "Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule*", J. Biol. Chem, 274, pp.559~562 (1999)
  36. Brown, E. J., "Integrin-associated protein(CD47)and its ligands", Trends Cell Biol, 11, pp.130~135 (2001)
  37. Xuan, W., "The chemotaxis of M1 and M2macrophages is regulated by different chemokines", J. Leukoc. Biol, 97, pp.61~69 (2015)
  38. Zheng, Y., "Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer", Cancer Lett, 499, pp.148~163 (2021)
  39. Raulet, D. H., "Regulation of ligands for the NKG2D activating receptor", Annu. Rev. Immunol, 31, pp.413~441 (2013)
  40. Zhao, P., "c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation", Cancers, 14, pp.457~ (2022)
  41. Hanahan, D., "Hallmarks of Cancer : The Next Generation", Cell, 144, pp.646~674 (2011)
  42. Liu, Y., "NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model", Cancer Res, 78, pp.3709~3717 (2018)
  43. Zhu, M., "Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis", Cancer Res, 81, pp.1813~1826 (2021)
  44. Saito, M., "Identification of candidate responders for anti-PD-L1", PD-1immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer, 2018, pp.8, 310~314
  45. Gius, D., "Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach", Cancer Cell, 6, pp.361~371 (2004)
  46. Rudin, C. M., "Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data", Nat. Rev. Cancer, 19, pp.289~297 (2019)
  47. Gay, C. M., "Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities", Cancer Cell, pp.346~360.e7 (2021)
  48. Shi, Y., "Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1", Cell, 119, pp.941~953 (2004)
  49. Shi, Y. -J., "Regulation of LSD1 Histone Demethylase Activity by Its Associated Factors", Mol. Cell, 19, pp.857~864 (2005)
  50. Augert, A., "Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition", Sci. Signal, 12, pp.eaau2922~ (2019)
  51. Bernstein, B. E., "Methylation of histone H3 Lys 4 in coding regions of active genes", Proc. Natl Acad. Sci, 99, pp.8695~8700 (2002)
  52. Bernstein, B. E., "Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse", Cell, 120, pp.169~181 (2005)
  53. Santos-Rosa, H., "Active genes are tri-methylated at K4 of histone H3", Nature, 419, pp.407~411 (2002)
  54. Pokholok, D. K., "Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast", Cell, 122, pp.517~527 (2005)
  55. Mohammad, H. P., "A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC", Cancer Cell, 28, pp.57~69 (2015)
  56. Takagi, S., "LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B", Cancer Res, 77, pp.4652~4662 (2017)
  57. Oser, M. G., "The KDM5A", RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis, 2019, pp.33, 1718~1738
  58. Best, S. A., "Harnessing Natural Killer Immunity in Metastatic SCLC", J. Thorac. Oncol, 15, pp.1507~1521 (2020)
  59. Mahadevan, N. R., "Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity", Cancer Disco, 11, pp.1952~1969 (2021)
  60. Nguyen, E. M., "Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC", J. Thorac. Oncol, 17, pp.1014~1031 (2022)
  61. Shepherd, F. A., "The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer", J. Thorac. Oncol, 2, pp.1067~1077 (2007)
  62. Torre, L. A., "lobal cancer statistics, 2012", Ca. Cancer J. Clin, 65, pp.87~108 (2015)
  63. Denny, S. K., "Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility", Cell, 166, pp.328~342 (2016)
  64. Dooley, A. L., "Nuclear factor I", B is an oncogene in small cell lung cancer, 2011, pp.25, 1470~1475
  65. Wu, N., "NFIB overexpression cooperates with Rb", p53 deletion to promote small cell lung cancer, 2016, pp.7, 57514~57524
  66. Semenova, E. A., "Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients", Cell Rep, 16, pp.631~643 (2016)
  67. Fane, M. E., "NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF", eBioMedicine, 16, pp.63~75 (2017)
  68. Esteller, M., "Epigenetic gene silencing in cancer: the DNA hypermethylome", Hum. Mol. Genet, 16, pp.R50~R59 (2007)
  69. Doi, A., "Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts", Nat. Genet, 41, pp.1350~1353 (2009)
  70. Yang, J., "Guidelines and definitions for research on epithelial–mesenchymal transition", Nat. Rev. Mol. Cell Biol, 21, pp.341~352 (2020)
  71. Hou, J. -M., "Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer", J. Clin. Oncol, 30, pp.525~532 (2012)
  72. Kim, D. -W., "Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer", Genes Dev, 30, pp.1289~1299 (2016)
  73. Jia, D., "Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition", Cancer Disco, 8, pp.1422~1437 (2018)
  74. Ko, J., "Mechanisms of small cell lung cancer metastasis", EMBO Mol. Med, 13, pp.e13122~ (2021)
  75. Vaz, M., "Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations", Cancer Cell, 32, pp.360~376 (2017)
  76. Anzalone, G., "Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients", Sci. Rep, 9, pp.15682~ (2019)
  77. Bersaas, A., "Epithelialmesenchymal transition and FOXA genes during tobacco smoke carcinogen induced transformation of human bronchial epithelial cells", Toxicol. Vitr, 35, pp.55~65 (2016)
  78. Liu, Y., "Epithelial-mesenchymal transition and cancer stem cells, mediated by a long non-coding RNA, HOTAIR, are involved in cell malignant transformation induced by cigarette smoke extract", Toxicol. Appl. Pharmacol, 282, pp.9~19 (2015)
  79. Bhat, S. A., "Long non-coding RNAs: Mechanism of action and functional utility", Non-Coding RNA Res, 1, pp.43~50 (2016)
  80. Lu, L., "Posttranscriptional silencing of the lncRNA MALAT1 by miR-217inhibits the epithelial–mesenchymal transition via enhancer of zeste homolog 2in the malignant transformation of HBE cells induced by cigarette smoke extract", Toxicol. Appl. Pharmacol, 289, pp.276~285 (2015)
  81. Tsai, M. -C., "Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes", Science, 329, pp.689~693 (2010)
  82. Byers, L. A., "Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1", Cancer Disco, 2, pp.798~811 (2012)
  83. Stewart, C. A., "Dynamic variations in epithelial-to-mesenchymal transition(EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer", Oncotarget, 8, pp.28575~28587 (2017)
  84. Gardner, E. E., "Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis", Cancer Cell, 31, pp.286~299 (2017)
  85. Kadoch, C., "Mammalian SWI", SNF chromatin remodeling complexes and cancer : Mechanistic insights gained from human genomics, 2015, pp.1, e1500447~
  86. Fernando, T. M., "Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131, 668 cancer patients", Nat. Commun, 11, pp.5551~ (2020)
  87. Concepcion, C. P., "Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung", Cancer Disco, 12, pp.562~585 (2022)
  88. Yan, H. -B., "Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription", Carcinogenesis, 35, pp.867~876 (2014)
  89. Tomihara, H., "Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress", Cancer Res, 81, pp.332~343 (2021)
  90. Sasaki, T., "Tumor progression by epithelial-mesenchymal transition in ARID1A-and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma", Virchows Arch, 480, pp.1063~1075 (2022)
  91. Kim, J., "SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer", Cancers, 13, pp.5474~ (2021)
  92. Lamar, J. M., "The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain", Proc. Natl Acad. Sci, 109, pp.E2441~E2450 (2012)
  93. Ireland, A. S., "MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate", Cancer Cell, 38, pp.60~78.e12 (2020)
  94. Terashima, M., "Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells", Biochem. Biophys. Res. Commun, 490, pp.1407~1413 (2017)
  95. Zha, L., "Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells", Med. Oncol, 33, pp.21~ (2016)
  96. Choi, H. -J., "UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1", EMBO Rep, 16, pp.1288~1298 (2015)
  97. Taki, M., "Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition", Clin. Cancer Res, 27, pp.4669~4679 (2021)
  98. Mullins, R. D. Z., "Epithelial–Mesenchymal Plasticity in Tumor Immune Evasion", Cancer Res, 82, pp.2329~2343 (2022)
  99. Qiu, Z., "CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter", Theranostics, 9, pp.4717~4729 (2019)
  100. Yang, F., "LncRNA HOTAIR regulates the expression of E-cadherin to affect nasopharyngeal carcinoma progression by recruiting histone methylase EZH2 to mediate H3K27 trimethylation", Genomics, 113, pp.2276~2289 (2021)
  101. Fillmore, C. M., "EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors", Nature, 520, pp.239~242 (2015)

관련 논문AI추천

The New Way to Define Key Oncogenic Drivers of Small Cell Lung Cancer김기범한국발생생물학회 · 발생과 생식2023 · 제27권 제1호Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective정광원, Ming Li Jin생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer신현석, 이승룡, 이진환, 최주환대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancerCho Jae-Won, Hong Min Hee, Kim Hye Ryun, Lee Chang Young, Lee Insuk, Park Seong Yong, Shim Hyo Sup생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexin생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Tumor-suppressive functions of protein lysine methyltransferases조재열, Aziz Nur, Hong Yo Han, Kim Han Gyung, Kim Ji Hye생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권

이 간행물의 다른 논문 (191건)

Particulate matter promotes cancer metastasis through increased HBEGF expression in macrophages이효진, Park Jun-Young, Lee Moo-Seung, Kim Dae-Soo, Son Mi-Young, Jeong Jinyoung, 박영준, Cho Young-Lai, Lee Seon-Jin, Park Seung-Ho, Yoon Sung-Jin, Choi Song, Jung Jaeeun, Park Young-Ho, Seo Jinho, Lee Jungwoon, Kim Jang-Seongpp. 1-12WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function권호근, 김현석, Yoon Hyun Ju, Kim Gi-Cheon, Oh Sejin, Kim Hakhyun, Kim Yong Keon, Lee Yunji, Kim Min Seo, Kwon Gino, Ok Yeon-Supp. 1-14Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagyFeng Ji, Wu Yong, Zhou Jing, Dai Hui-Qi, Zhu Guang-Zhi, Chen Pan-Hong, Wang Li-Ming, Lu Guang, Liao Xi-Wen, Lu Pei-Zhi, Su Wen-Jing, Hooi Shing Chuan, Ye Xin-Pin, Shen Han-Ming, Peng Tao, Lu Guo-Dongpp. 1-15Hypoxia-induced circRNF13 promotes the progression and glycolysis of pancreatic cancerZhao Qiuyan, Zhu Zhonglin, Xiao Wenqin, Zong Guanzhao, Wang Chuanyang, Jiang Weiliang, Li Kai, Shen Jie, Guo Xingya, Cui Jianhua, Guo Lihong, Wan Rongpp. 1-15The transcriptional profile of keloidal Schwann cellsDireder Martin, Wielscher Matthias, Weiss Tamara, Laggner Maria, Copic Dragan, Klas Katharina, Bormann Daniel, Vorstandlechner Vera, Tschachler Erwin, Jan Ankersmit Hendrik, Mildner Michaelpp. 1-15
원문 보기